RT Journal Article
T1 Sex- and site-specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort.
A1 Reichmann, Robin
A1 Nimptsch, Katharina
A1 Pischon, Tobias
A1 Gunter, Marc J
A1 Jenab, Mazda
A1 Eriksen, Anne Kirstine
A1 Tjonneland, Anne
A1 Janke, Jürgen
A1 Katzke, Verena
A1 Kaaks, Rudolf
A1 Schulze, Matthias B
A1 Eichelmann, Fabian
A1 Masala, Giovanna
A1 Sieri, Sabina
A1 Pasanisi, Fabrizio
A1 Tumino, Rosario
A1 Giraudo, Maria Teresa
A1 Rothwell, Joseph
A1 Severi, Gianluca
A1 Jakszyn, Paula
A1 Sanchez-Perez, Maria Jose
A1 Amiano, Pilar
A1 Colorado-Yohar, Sandra M
A1 Guevara, Marcela
A1 van Guelpen, Bethany
A1 Aglago, Elom K
A1 Heath, Alicia K
A1 Smith-Byrne, Karl
A1 Weiderpass, Elisabete
A1 Aleksandrova, Krasimira
K1 EPIC
K1 Colorectal cancer
K1 Immunity
K1 Lipocalin 2
K1 Metabolism
AB Experimental research has uncovered lipocalin 2 (LCN2) as a novel biomarker implicated in the modulation of intestinal inflammation, metabolic homeostasis, and colon carcinogenesis. However, evidence from human research has been scant. We, therefore, explored the association of pre-diagnostic circulating LCN2 concentrations with incident colorectal cancer (CRC) in a nested case-control study within the in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. LCN2 was measured in 1267 incident CRC cases matched to 1267 controls using incidence density sampling. Conditional logistic regression was used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) according to tumor subsite and sex. Weighted Cox proportional hazard regression was used to explore associations by adiposity status. In multivariable-adjusted analyses, the IRR [95% CI] per doubling in LCN2 concentration was 1.16 [0.98-1.37] for CRC overall, 1.26 [1.00-1.59] for colon cancer, and 1.08 [0.85-1.38] for rectal cancer. The association for colon cancer was more pronounced in women (IRR [95% CI], 1.66 [1.20-2.30]) and for proximal colon cancer (IRR [95% CI], 1.96 [1.15-3.34]), whereas no association was seen in men and distal colon cancer. The association for colon cancer was positive in individuals with high waist circumference (hazard ratio [95% CI], 1.69 [1.52-1.88]) and inverse in individuals with low waist circumference (hazard ratio [95% CI], 0.86 [0.76-0.98], P interaction<0.01). Overall, these data suggest that pre-diagnostic LCN2 concentrations were positively associated with colon cancer, particularly occurring in the proximal colon, in women and among individuals with abdominal adiposity.
PB International Union Against Cancer
YR 2024
FD 2024-11-07
LK https://hdl.handle.net/10668/24330
UL https://hdl.handle.net/10668/24330
LA en
NO Reichmann R, Nimptsch K, Pischon T, Gunter MJ, Jenab M, Eriksen AK, et al. Sex- and site-specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort. Int J Cancer. 2024 Nov 7
NO The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council, Region Skåne and Region Västerbotten (Sweden); Cancer Research UK (14,136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1,000,143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom).
DS RISalud
RD Apr 7, 2025